EXICURE, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
EXICURE, INC. (XCUR) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-27.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2023-03-27
- EXICURE, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2022-12-31 was $0.00.
- EXICURE, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2022-09-30 was $0.00, a 100.00% decline year-over-year.
- EXICURE, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2021-12-31 was $0.00, a 100.00% decline year-over-year.
- EXICURE, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2021-09-30 was $166.00K.
- EXICURE, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- EXICURE, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2021 was $243.00K, a 53.80% decline from fiscal 2020.
- EXICURE, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2020 was $526.00K, a 205.81% increase from fiscal 2019.
- EXICURE, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2019 was $172.00K, a 290.91% increase from fiscal 2018.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27 | $0.00 derived: sum of 2 quarters · filed 2023-03-27 | $0.00 10-K · filed 2023-03-27 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $0.00 10-Q · filed 2022-11-14 | ||
| 2022-06-30 | $0.00 10-Q · filed 2022-08-15 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27 | $166.00K derived: sum of 2 quarters · filed 2023-03-27 | $43.00K derived: sum of 3 quarters · filed 2023-03-27 | $243.00K 10-K · filed 2023-03-27 |
| 2021-09-30 | $166.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $43.00K derived: sum of 2 quarters · filed 2022-11-14 | $243.00K 10-Q · filed 2022-11-14 | $695.00K derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | -$123.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $77.00K 10-Q · filed 2022-08-15 | $529.00K derived: sum of 3 quarters · filed 2022-08-15 | $514.00K derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | $200.00K 10-Q · filed 2022-05-16 | $652.00K derived: sum of 2 quarters · filed 2022-05-16 | $637.00K derived: sum of 3 quarters · filed 2022-05-16 | |
| 2020-12-31 | $452.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-25 | $437.00K derived: sum of 2 quarters · filed 2022-03-25 | $526.00K 10-K · filed 2022-03-25 | |
| 2020-09-30 | -$15.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-19 | $74.00K 10-Q · filed 2021-11-19 | ||
| 2020-06-30 | $89.00K 10-Q · filed 2021-08-12 | |||
| 2019-12-31 | $159.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $155.00K derived: sum of 2 quarters · filed 2021-03-11 | $172.00K 10-K · filed 2021-03-11 | |
| 2019-09-30 | -$4.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $13.00K 10-Q · filed 2020-11-12 | ||
| 2019-06-30 | $17.00K 10-Q · filed 2020-08-12 | |||
| 2018-12-31 | -$7.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-10 | $26.00K derived: sum of 2 quarters · filed 2020-03-10 | $26.00K derived: sum of 3 quarters · filed 2020-03-10 | $44.00K 10-K · filed 2020-03-10 |
| 2018-09-30 | $33.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $33.00K derived: sum of 2 quarters · filed 2019-11-07 | $51.00K 10-Q · filed 2019-11-07 | $51.00K derived: sum of 4 quarters · filed 2019-11-07 |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $18.00K 10-Q · filed 2019-08-08 | $18.00K derived: sum of 3 quarters · filed 2019-09-23 | $18.00K derived: sum of 4 quarters · filed 2019-09-23 |
| 2018-03-31 | $18.00K 10-Q · filed 2019-05-08 | $18.00K derived: sum of 2 quarters · filed 2019-09-23 | $18.00K derived: sum of 3 quarters · filed 2019-09-23 | $18.00K derived: sum of 4 quarters · filed 2019-09-23 |
| 2017-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2019-09-23 | $0.00 derived: sum of 2 quarters · filed 2019-09-23 | $0.00 derived: sum of 3 quarters · filed 2019-09-23 | $202.00K 10-K/A · filed 2019-09-23 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $0.00 derived: sum of 2 quarters · filed 2018-11-06 | $202.00K 10-Q · filed 2018-11-06 | $217.00K derived: sum of 4 quarters · filed 2018-11-06 |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-06 | $202.00K 10-Q · filed 2018-08-06 | $217.00K derived: sum of 3 quarters · filed 2018-08-06 | |
| 2017-03-31 | $202.00K 10-Q · filed 2018-05-15 | $217.00K derived: sum of 2 quarters · filed 2018-05-15 | ||
| 2016-12-31 | $15.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-09 | $63.00K 10-K · filed 2018-03-09 | ||
| 2016-09-30 | $48.00K 10-Q · filed 2017-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |